Related references
Note: Only part of the references are listed.Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation
Gavin O'Mahony et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum
Naoki Teno et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Giovanni Targher et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
Sachiho Miyata et al.
SCIENTIFIC REPORTS (2021)
Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
Moritz Helmstadter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Epidemiology of chronic liver diseases in the USA in the past three decades
Zobair M. Younossi et al.
GUT (2020)
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Jiyu Zhou et al.
NATURE COMMUNICATIONS (2020)
N1-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR)
Arisa Masuda et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Design and Structural Optimization of Dual FXR/PPARδ Activators
Simone Schierle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular tuning of farnesoid X receptor partial agonism
Daniel Merk et al.
NATURE COMMUNICATIONS (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Nonacidic Chemotype Possessing N-Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists
Naoki Teno et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
R. Pencek et al.
DIABETES OBESITY & METABOLISM (2016)
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
Christopher L. Bowlus
HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2016)
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia
Michael J. Genin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Wedelolactone Regulates Lipid Metabolism and Improves Hepatic Steatosis Partly by AMPK Activation and Up-Regulation of Expression of PPARα/LPL and LDLR
Yun Zhao et al.
PLOS ONE (2015)
Nuclear receptor full-length architectures: confronting myth and illusion with high resolution
Fraydoon Rastinejad et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Quinoxaline-2,3-diones: potential D-amino acid oxidase (DAAO) inhibitors
Dongsheng Xie et al.
MEDICINAL CHEMISTRY RESEARCH (2014)
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice
Iker Uriarte et al.
GUT (2013)
Novel Research Strategies of Benzimidazole Derivatives: A Review
Kuldipsinh Barot et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2013)
The therapeutic journey of benzimidazoles: A review
Yogita Bansal et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Trichlorophenyl Formate: Highly Reactive and Easily Accessible Crystalline CO Surrogate for Palladium-Catalyzed Carbonylation of Aryl/Alkenyl Halides and Triflates
Tsuyoshi Ueda et al.
ORGANIC LETTERS (2012)
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Jang Hyun Choi et al.
NATURE (2011)
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Jang Hyun Choi et al.
NATURE (2010)
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
Jonathan Y. Bass et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Use of thiazolidinediones and fracture risk
Christian Meier et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
Adwoa Akwabi-Ameyaw et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
TZDs and Bone: A Review of the Recent Clinical Evidence
Ann V. Schwartz
PPAR RESEARCH (2008)
Partial agonists activate PPARγ using a helix 12 independent mechanism
John B. Bruning et al.
STRUCTURE (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Farnesoid X receptor is essential for normal glucose homeostasis
K Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease
M Hamaguchi et al.
ANNALS OF INTERNAL MEDICINE (2005)
The metabolic syndrome:: Peroxisome proliferator-activated receptor γ and its therapeutic modulation
M Gurnell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
C/EBP alpha induces adipogenesis through PPAR gamma: a unified pathway
ED Rosen et al.
GENES & DEVELOPMENT (2002)
27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells
X Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
N Maeda et al.
DIABETES (2001)
Nuclear hormone receptors and gene expression
A Aranda et al.
PHYSIOLOGICAL REVIEWS (2001)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Identification of a chemical tool for the orphan nuclear receptor FXR
PR Maloney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
